Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Modality
Small molecule
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02806817CT.gov ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ME 344 (this asset) | Centro Nacional de Investigaciones Oncologicas CARLOS III | Early P1 | CC · 43 |
| Trastuzumab | SWOG Cancer Research Network | P4 | BBB |
| Tamoxifen | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P3 | BBB |
| Trastuzumab Deruxtecan | SWOG Cancer Research Network | P4 | BB |
| Letrozole | OHSU Knight Cancer Institute | P4 | BB |
| Exemestane | Dartmouth-Hitchcock Medical Center | P4 | BB |
| Zoledronate | Washington University School of Medicine | P4 | BB |
+42 more in the Breast Carcinoma cohort
Other indications for ME 344
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1/2 | CC · 44 |
| Her2-Receptor Negative Breast Cancer | — | Early P1 | CC · 43 |
| Breast Cancer | — | Early P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ME 344 in Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/me-344-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →